Pre-IPO Cryofocus Medtech (Shanghai) - The Industry, the Business and the Concerns

411 Views18 Jul 2022 09:04
Cryofocus Medtech’s products do have technical advantages, but the commercialization outlook remains to be seen due to large price reduction after entering NRDL and uncertainties on market acceptance.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x